Core Viewpoint - Sinovac Biotech Ltd. has provided an update regarding the Antigua High Court's interlocutory order affecting the company's board composition and corporate actions pending trial [1] Group 1: Corporate Governance - The Antigua High Court has issued an interlocutory order that governs the board composition of Sinovac Biotech Ltd. [1] - The order also impacts corporate actions of the company while awaiting trial [1] Group 2: Financial Engagement - Sinovac Biotech Ltd. has engaged Zhonghua Certified Public Accountants LLP as its independent auditor [1] - Zhonghua is an affiliate of the global accounting network UHY International [1]

Core Points - Heng Ren Silk Road Investments LLC has reported strong support from over 100 independent Sinovac shareholders for the immediate payment of a previously declared $19.00 dividend [1] - Sinovac's stock has been halted from trading since 2019, causing shareholders to miss out on significant profits from the COVID-19 vaccine, CoronaVac, which generated billions in sales during the pandemic [2] - The board had previously paid a $55.00 dividend in July 2025 as partial compensation for unpaid dividends during the trading halt [2] - An additional $19.00 dividend was declared on June 17, 2025, aimed at compensating independent shareholders for dividends that were paid to certain affiliates and insiders [3] - Despite the declaration, Sinovac has not provided record and payment dates for the promised dividend, which is unexpected given the board's commitment to pay dividends [4] - Peter Halesworth, founder of Heng Ren, emphasized the need for the board to respect the wishes of independent shareholders and set payment dates for the dividend [5] Company Actions - Heng Ren Silk Road Investments LLC is actively campaigning for the payment of the $19.00 dividend and has organized a webinar for shareholders to discuss voting processes and related issues [6] - An open resolution has been sent to Sinovac's shareholders urging the payment of the special dividend before the upcoming board vote on July 8 [7]

Core Viewpoint - SINOVAC Biotech Ltd. has appointed UHY LLP as its independent auditor, marking a significant step towards improving transparency and resuming trading on NASDAQ [1][3]. Company Overview - SINOVAC is a leading biopharmaceutical company in China, focusing on the research, development, manufacturing, and commercialization of vaccines for infectious diseases [3][4]. - The company's product portfolio includes vaccines for COVID-19, hepatitis A, and other infectious diseases [4][5]. Auditor Engagement - UHY will audit SINOVAC's financial statements for the years ending December 31 from 2021 to 2025, including internal control audits for 2024 and 2025 [2]. - The company plans to file Form 20Fs and Form 6-Ks to comply with SEC and NASDAQ requirements [2]. Commitment to Transparency - The appointment of UHY is seen as a commitment to robust financial oversight and transparency, facilitating the goal of resuming trading on NASDAQ [3]. Future Plans - SINOVAC is dedicated to ongoing vaccine research and development, with plans to explore global market opportunities and enhance trade and cooperation with other countries [7].

Core Viewpoint - Sernova Biotherapeutics has entered into a Collaborative Research Agreement with Eledon Pharmaceuticals to utilize Eledon's immunosuppressive agent, tegoprubart, in Sernova's Phase 1/2 clinical trial for its Cell Pouch Bio-hybrid Organ aimed at treating patients with Type 1 Diabetes (T1D) [1][2]. Group 1: Collaboration and Clinical Trial Details - Eledon will supply tegoprubart, an investigational anti-CD40L antibody, to replace tacrolimus in Cohort C of the clinical trial, addressing the limitations of tacrolimus in islet cell therapy for T1D [2][3]. - The trial led by Dr. Piotr Witkowski showed that T1D patients receiving islet transplants with tegoprubart achieved normal blood sugar levels and insulin independence, with islet engraftment rates three to five times higher than those receiving tacrolimus [3]. Group 2: Company Statements and Future Outlook - Sernova's CEO expressed optimism about the combination of their Cell Pouch technology with tegoprubart, suggesting it could lead to faster insulin independence with reduced toxicity to islet cells [4]. - Eledon's CEO highlighted the potential of tegoprubart to protect transplanted cells without the toxicities associated with standard immunosuppressive treatments, aiming to transform the treatment landscape for T1D [4]. Group 3: Company Background - Sernova Biotherapeutics is focused on developing regenerative medicine therapeutics that integrate its Cell Pouch with human donor cells or stem-cell derived islet-like clusters to create bio-hybrid organs for treating T1D and other chronic diseases [5].

Core Viewpoint - Sernova Biotherapeutics is making significant progress in its mission to develop a functional cure for type 1 diabetes (T1D) through its innovative Cell Pouch Bio-hybrid Organ technology, while also undergoing leadership changes and pursuing financing opportunities [1][3]. Company Developments - Jonathan Rigby has been appointed as Interim Chair of the board of directors, effective immediately, while the company searches for a new independent director to take on the Chair role [1]. - The company is actively engaged in financing discussions with GoldTrack Ventures and the Kingdom of Saudi Arabia, which are seen as promising partnerships [2]. - Sernova has released encouraging clinical data and formed a Clinical Advisory Board, indicating progress in its strategic and operational initiatives [3]. - The departure of Modestus Obochi, the Chief Business Officer, has been announced, with the company expressing gratitude for his contributions [3]. Technology and Innovation - Sernova is focused on developing regenerative medicine therapeutics that combine its Cell Pouch with human donor cells or stem-cell derived islet-like clusters, in collaboration with Evotec, to create Bio-hybrid Organs aimed at treating T1D and thyroid disorders [4].

Company Overview - Sernova Biotherapeutics is a clinical-stage company focused on developing regenerative medicine therapeutics, specifically its Cell Pouch Bio-hybrid Organ as a functional cure for type 1 diabetes (T1D) [3] - The company collaborates with Evotec to create Bio-hybrid Organs that integrate human donor cells or stem-cell derived islet-like clusters with its Cell Pouch [3] Recent Developments - Mr. Ross Haghighat resigned as Chair of Sernova Biotherapeutics on May 24, 2025, and his resignation was accepted by the Board of Directors [2] - The Board expressed gratitude for Mr. Haghighat's service and wished him well in his future endeavors [2] Product Focus - The Bio-hybrid Organ developed by Sernova consists of non-biomaterials, such as the Cell Pouch, combined with living tissues to restore or enhance the function of compromised organs [3] - The initial focus of Sernova's innovative approach is on treating chronic diseases, particularly T1D and thyroid disorders [3]

Core Insights - Sernova Biotherapeutics has formed a Clinical Advisory Board to guide the development of its Cell Pouch Bio-hybrid Organ as a potential functional cure for type 1 diabetes (T1D) [1][7] Group 1: Clinical Advisory Board Composition - The board consists of five members, chaired by Dr. Robert Gabbay, who has extensive experience in diabetes care and research [2] - Other notable members include: - Dr. Mark Atkinson, a leading researcher in T1D with over 750 publications [3] - Dr. Melena Bellin, an expert in islet cell transplantation for T1D [4] - Dr. Andrew Posselt, a surgeon-scientist specializing in transplant immunology [5] - Dr. Holger Russ, who focuses on regenerative medicine and autoimmune type 1 diabetes [6] Group 2: Company Overview and Technology - Sernova Biotherapeutics is a clinical-stage company developing regenerative medicine therapeutics, specifically the Cell Pouch integrated with human donor cells or stem-cell derived islet-like clusters [8] - The Cell Pouch is designed to create bio-hybrid organs that restore or enhance organ function, initially targeting T1D and thyroid disorders [9]

Core Insights - Sernova Biotherapeutics announced positive interim data from its Phase 1/2 clinical trial for its Cell Pouch Bio-hybrid Organ aimed at treating type 1 diabetes (T1D) [1][2] Group 1: Clinical Trial Results - Interim data from 12 patients show that 8 achieved insulin independence, with islet cell engraftment and improved glycemic control [2][3] - 7 out of 12 patients demonstrated C-peptide levels of 0.3 ng/mL or greater, indicating successful islet cell engraftment [4] - 9 of 12 patients had HbA1c levels below the ADA recommended threshold of <7.0%, with one patient showing a 24% reduction in HbA1c from 10.3% to 7.8% [5] Group 2: Patient Quality of Life Improvements - 11 of 12 patients reported improved awareness of hypoglycemia and increased sensitivity to severe hypoglycemic symptoms [7] - 10 of 12 patients showed a reduction in fear of hypoglycemia as measured by the Hypoglycemia Fear Survey-II [8] - 10 of 12 patients experienced a decrease in diabetes distress, indicating improved emotional well-being related to managing T1D [9] Group 3: Future Developments - Clinical trials with iPSC islet-like clusters from Evotec are expected to begin in 2026 after the completion of Cohort C [3] - The study is on track to meet its primary and secondary endpoints, with Cohort C anticipated to initiate in the second half of 2025 [2][10] - The Cell Pouch Bio-hybrid Organ is positioned as a potential functional cure for T1D, combining human donor cells or stem-cell derived islet-like clusters [11]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ...

Exhibit 99.1 SINOVAC Reports Unaudited First Half of 2023 Financial Results BEIJING, China, August 15, 2023 /Business Wire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, announced today its unaudited financial results for the six months ended June 30, 2023. First Half of 2023 Financial Summary · Sales for the six months ended June 30, 2023 were $140.4 million, compared to $1.2 billion in the prior year period. · The Company pos ...